Back

Impaired endogenous fibrinolysis in STEMI patients undergoing PPCI is an independent predictor of recurrent cardiovascular events -the RISK PPCI study

26 August 2018 (15:01 - 15:15)
Organised by:
Congress Presentation Part of: No-reflow prevention and pathophysiology Thrombosis, Platelets, and Coagulation ESC Premium Access ESC Congress 2018

About the speaker

Photo
Doctor Mohamed Farag

Newcastle Hospitals NHS Trust, Newcastle Upon Tyne (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
No-reflow: prevention and pathophysiology - State of the art
Professor P. Wenzel (Mainz, DE)
Slides Video
Presentation thumbnail
The modulation of miR-129-3p levels in coronary thrombi after primary PCI discloses a novel potential mechanism underlying the no reflow phenomenon
Doctor S. De Rosa (Catanzaro, IT)
Abstract
Presentation thumbnail
Multicenter randomized clinical trial of the efficacy and safety of intravenous quercetin in patients with ST-elevation acute myocardial infarction
Doctor S. Kozhukhov (Kiev, UA)
Abstract
Presentation thumbnail
The future of preventing reperfusion injury: achievable anytime soon?
Doctor D. Pinto (Boston, US)
Slides Video

Access the full session

Session thumbnail
No-reflow prevention and pathophysiology

The Event

Event poster

ESC Congress 2018

26 August 2018 15:01 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources